logo
Weight-loss jabs may need to be taken for life, experts warn

Weight-loss jabs may need to be taken for life, experts warn

Yahoo5 hours ago

Weight-loss jabs may have to be used for many years if the long-term benefits to patients and the NHS are to be realised, experts have said.
The drugs are sold under brand names like Mounjaro and Wegovy and work by reducing food cravings.
Obese patients can currently be prescribed the jabs on the NHS after being referred to specialist weight loss clinics, which are usually located in hospitals.
Hundreds of thousands of people also access the medication privately at pharmacies.
There have been warnings about buying potentially unsafe jabs online from unregulated retailers and potentially missing out on wraparound support.
Experts said the jabs should not be seen as the first option in weight loss and should be used in conjunction with lifestyle changes, such as eating more healthily and increasing exercise.
Professor Graham Easton, a GP who has been using weight loss jabs himself, said: 'I think it's a major issue about the proper funding and resourcing of not only the GPs in the surgeries but also the wraparound care we talked about.
'I think the other issue is that so far, to my knowledge, the NHS and National Institute for Health and Care Excellence have talked about this being something you take for two years, and that's probably related to data from research studies.
'But as we discussed, this is likely to be a lifelong commitment if it is going to be worthwhile to the NHS.
'There's no point in most people taking it for a couple of years and then have the weight bouncing back.
'You can argue possibly you're about to prepare for surgery or something, but in most cases it doesn't make any sense.
'Then I think there's a big issue around access. Most obesity occurs in poorer populations as wealthier populations tend to not be so affected.
'There's a massive sort of socio-economic inequality and there is a worry about this driving that inequality even further.
'Unless the NHS makes sure that these are available across the board equally, I think that's a major risk.'
Prof Easton said recent studies had shown people who stopped taking the drugs had put the weight they lost back on within around a year.
'That's often true of any diet, people would say, and that's certainly my experience of having wrestled with my weight in diets over the years,' he said.
'All I would say that I found interesting from that review was that they were suggesting perhaps that weight returns even quicker after having been on GLP-1 drugs.
'Then speculating, because there was no way of knowing from that review, that perhaps it's because people are not changing the behaviours we've been talking about like exercise and other lifestyle changes, just relying on the drugs.
'When you stop them, of course, you're going to put weight back on. The switch is turned back off, or whatever it was.
'I mean very similar to, for example, statins or anti-hypertensive blood pressure medications, if you want lifelong effects, you have to keep on them lifelong.'
Prof Easton was speaking at an event at the Cheltenham Science Festival discussing the growing use of weight loss drugs with neurophysiologist Dr Simon Cork and consultant endocrinologist and obesity expert Dr Tony Goldstone.
Dr Cork said the jabs have an important role to play in losing weight but are part of wider changes to diet and lifestyle.
'I think we have to understand that diet is always limited. People will tend to lose on average around 5% of their body weight on a diet,' he said.
'But you're hungry, you're miserable, you're tired, your wife hates you because you're so grumpy, you're not going to continue with that.
'But we should absolutely all be looking at our diet and all changing our diet, and doing something.'
Dr Goldstone said weight loss drugs had been used in the treatment of diabetes for over a decade and had benefits of reducing the risk of developing other conditions.
'We're now in the third and fourth generation of these drugs, but the first generation of these drugs we've been using for 15 years for diabetes,' he said.
'There is nothing of concern that has emerged. In fact, all we're seeing are benefits. I'm not too worried about longer term side effects coming out.
'There is no real biological reason why there should be dangerous side-effects in the way that we know these drugs work.
'The benefits of the weight loss improvement in the diabetes are actually by themselves helping health and preventing other diseases, like cancer, heart attacks, renal failure, and potentially even reducing the risk of Alzheimer's disease.
'All those benefits, even if there was something that we hadn't really thought of that emerged down the line, I suspect that the harm of that is outweighed by the potential benefits of weight loss improvement in diabetes control.'
Dr Cork said no drug is without side-effects and previous weight loss medications had failed because of them.
'There are side-effects, there are some concerning side-effects that tend to be very rare, but then you can monitor for those side-effects,' he said.
'As long as you're getting the correct care, as long as your GP is aware that you're taking them, then those should be identified.
'If you do find those side-effects, you can stop taking the drug.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New boss confirmed for NHS healthcare trust
New boss confirmed for NHS healthcare trust

Yahoo

time14 minutes ago

  • Yahoo

New boss confirmed for NHS healthcare trust

A new chief executive has been announced at a health trust where the current boss is stepping down after more than 37 years in the NHS. Surrey and Sussex Healthcare NHS Trust (SASH) said Andrew Hines would take over in the autumn. He currently works at Barts Health NHS Trust in London as executive director for group development. Angela Stevenson, who started her career as a student nurse in Glasgow in 1988, retires in August. Trust chairperson Anita Donley said she was pleased to be announcing Mr Hines as the next chief executive. "I know he will bring energy, commitment and dedication to this role, and his experience will be instrumental in leading the trust forward into the next stage of its journey as an acute provider," she added. Mr Hines said he was delighted and proud to be taking up the role. He added: "The trust provides vital services to a growing population across east Surrey and west Sussex. "I'm looking forward to working with its fantastic staff and building on relationships with partner organisations." The trust was formed in 1998, as a result of a merger between the East Surrey Healthcare NHS Trust and Crawley Horsham NHS Trust. It runs Crawley, Horsham, Caterham Dene and East Surrey hospitals. Follow BBC Surrey on Facebook, on X, and on Instagram. Send your story ideas to southeasttoday@ or WhatsApp us on 08081 002250. Hospital chief retiring after 37 years in NHS Thousands to benefit from new NHS hub Frailty unit cuts down hospital stays for elderly Surrey and Sussex NHS Trust

Ketamine crisis causing A&E influx
Ketamine crisis causing A&E influx

Yahoo

time14 minutes ago

  • Yahoo

Ketamine crisis causing A&E influx

Parts of Lancashire are in the grip of a "ketamine crisis" with the drug causing a surge in visits to A&E amongst those using it, councillors have been warned. County Councillor Daniel Matchett, who works as a mental health nurse, said he had witnessed a "massive influx of ketamine users" in A&E. It comes after a £10.6m grant was given to Lancashire County Council to prevent drug and alcohol-related deaths and help those with addiction issues. Machett said young people were "becoming dependant" on ketamine, a powerful horse tranquiliser and anaesthetic. Ketamine is a licensed drug and can be prescribed medically. However, when misused, it can cause serious and sometimes permanent damage to the bladder, along with other health problems. The disturbing rise of ketamine abuse among young people Matchett told Lancashire County Council's cabinet meeting: "It's prevalent in festivals and everyday life – young people [are] becoming dependent on ketamine and it's a very sad thing to see." He agreed to meet with Progressive Lancashire opposition group leader Azhar Ali and other representatives from East Lancashire to discuss the issue, the Local Democracy Reporting Service said. "[There is a] ketamine crisis in places like Burnley…and there is a real need to learn from people who have gone through that experience," Lancashire County Councillor Ali said. The funding from the £10.6m grant aims to cut crime associated with drugs and save the lives of users. It will also be used to help those dependent on alcohol, the council said. In Lancashire, the lion's share of the cash – £8.1m – will go to the Change Grow Live charity to deliver improvements in both drug and alcohol treatment and rehabilitation, including individual placements. Five other organisations, Red Rose Recovery, The Well Communities, Lancashire Women, Active Lancashire and The Foxton, will receive grants of between £79,000 and £443,000 for their specialist work. Meanwhile, in-patient detox placements will be given £430,000 as part of a consortium with neighbouring local authorities. The council said the overall grant would be used to: Increase "peer support" to encourage uptake of the harm reduction services on offer in the county Enhance the out-of-hours support available to recovering addicts, including at weekends Support those in or at risk of entering the criminal justice system by providing "improved care pathways" to drug treatment services Listen to the best of BBC Radio Lancashire on Sounds and follow BBC Lancashire on Facebook, X and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230. Council gets £10m boost for drug and alcohol support Generation K: The disturbing rise of ketamine abuse among young people Hooked on ketamine - Gen Z's drug of choice Lancashire County Council Local Democracy Reporting Service

Opinion - Beyond MAHA: Defeating obesity requires a new strategy
Opinion - Beyond MAHA: Defeating obesity requires a new strategy

Yahoo

time14 minutes ago

  • Yahoo

Opinion - Beyond MAHA: Defeating obesity requires a new strategy

Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store